Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.95−0.10 (-9.87%)
Close on Nov 16, 2026Market cap $26.27MP/E –Yield –
Inmune Bio operating margin
Operating margin is operating income as a percentage of revenue.
Inmune Bio's operating margin for the twelve months ending Dec 31, 2025 was -94766.0%. For fiscal 2025 it was -94766.0%, against -304535.7% the year before. The highest annual figure on record is -6938.8% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -94766.0% | +209769.7 |
| FY2024 | Dec 31, 2024 | -304535.7% | −285348.0 |
| FY2023 | Dec 31, 2023 | -19187.7% | −12249.0 |
| FY2022 | Dec 31, 2022 | -6938.8% | +9167.9 |
| FY2021 | Dec 31, 2021 | -16106.6% | +95057.0 |
| FY2020 | Dec 31, 2020 | -111163.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -19810.0% | −5873.0 |
| Q1 FY2024 | Mar 31, 2024 | -78692.9% | −61790.2 |
| Q4 FY2023 | Dec 31, 2023 | -29925.0% | −24108.5 |
| Q3 FY2023 | Sep 30, 2023 | -19832.6% | −12237.7 |
| Q2 FY2023 | Jun 30, 2023 | -13937.0% | +25988.0 |
| Q1 FY2023 | Mar 31, 2023 | -16902.6% | −12928.4 |
| Q4 FY2022 | Dec 31, 2022 | -5816.5% | −276.6 |
| Q3 FY2022 | Sep 30, 2022 | -7594.9% | +56840.8 |
| Q2 FY2022 | Jun 30, 2022 | -39925.0% | +73775.0 |
| Q1 FY2022 | Mar 31, 2022 | -3974.2% | – |
| Q4 FY2021 | Dec 31, 2021 | -5539.9% | – |
| Q3 FY2021 | Sep 30, 2021 | -64435.7% | – |
| Q1 FY2021 | Mar 31, 2021 | -113700.0% | – |
See a number that looks wrong?